Targeting oxidative stress in embryonal rhabdomyosarcoma.

[1]  Daniella Yeheskely-Hayon,et al.  High levels of reactive oxygen species in gold nanoparticle-targeted cancer cells following femtosecond pulse irradiation , 2013, Scientific Reports.

[2]  James R. Anderson,et al.  Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2013, American journal of clinical pathology.

[3]  V. Mootha,et al.  MICU1 controls both the threshold and cooperative activation of the mitochondrial Ca²⁺ uniporter. , 2013, Cell metabolism.

[4]  A. McCullough.  Comprehensive genomic characterization of squamous cell lung cancers , 2013 .

[5]  Yang Liu,et al.  Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents. , 2012, Current drug targets.

[6]  K. Block,et al.  Aiding and abetting roles of NOX oxidases in cellular transformation , 2012, Nature Reviews Cancer.

[7]  Elaine R. Mardis,et al.  Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.

[8]  D. Hawkins,et al.  Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft‐tissue Sarcoma committee experience and rationale for current COG studies , 2012, Pediatric blood & cancer.

[9]  J. Auwerx,et al.  Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1. , 2012, European heart journal.

[10]  Michael C. Rusch,et al.  Integrated cross-species transcriptional network analysis of metastatic susceptibility , 2012, Proceedings of the National Academy of Sciences.

[11]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[12]  L. Borsu,et al.  Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways , 2011, Clinical Cancer Research.

[13]  J. Friedberg,et al.  Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo , 2011, Molecular Cancer Therapeutics.

[14]  S. Cameron,et al.  High‐resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis , 2011, Genes, chromosomes & cancer.

[15]  F. McCormick,et al.  Therapeutic strategies for targeting ras proteins. , 2011, Genes & cancer.

[16]  Benjamin R Arenkiel,et al.  Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. , 2011, Cancer cell.

[17]  N. Carter,et al.  Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.

[18]  Lingyun Ji,et al.  Combination of Vorinostat and Flavopiridol Is Selectively Cytotoxic to Multidrug-Resistant Neuroblastoma Cell Lines with Mutant TP53 , 2010, Molecular Cancer Therapeutics.

[19]  J. Friedberg,et al.  The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. , 2010, Blood.

[20]  O. Delattre,et al.  Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  James R. Anderson,et al.  Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Wagers,et al.  Muscling in: Uncovering the origins of rhabdomyosarcoma , 2010, Nature Medicine.

[23]  C. Dominici,et al.  RAS signaling dysregulation in human embryonal Rhabdomyosarcoma , 2009, Genes, chromosomes & cancer.

[24]  S. Ognjanovic,et al.  Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975‐2005 , 2009, Cancer.

[25]  E. Wagner,et al.  Signal integration by JNK and p38 MAPK pathways in cancer development , 2009, Nature Reviews Cancer.

[26]  G. Kardon,et al.  Embryonic and fetal limb myogenic cells are derived from developmentally distinct progenitors and have different requirements for beta-catenin. , 2009, Genes & development.

[27]  F. Sim,et al.  Malignant bone tumors. , 2001, Instructional course lectures.

[28]  Marc-André Elsliger,et al.  Rare cancer-specific mutations in PIK3CA show gain of function , 2007, Proceedings of the National Academy of Sciences.

[29]  S. Grant,et al.  RETRACTION: Flavopiridol and Histone Deacetylase Inhibitors Promote Mitochondrial Injury and Cell Death in Human Leukemia Cells That Overexpress Bcl-2 , 2006, Molecular Pharmacology.

[30]  S. Horvath,et al.  Statistical Applications in Genetics and Molecular Biology , 2011 .

[31]  Benjamin R. Arenkiel,et al.  Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. , 2004, Genes & development.

[32]  S. Oka,et al.  Differential effects of vitamin E and three hydrophilic antioxidants on the actinomycin D-induced and colcemid-accelerated apoptosis in human leukemia CMK-7 cell line , 2003, Molecular and Cellular Biochemistry.

[33]  Jiang Tian,et al.  Involvement of mitogen-activated protein kinases and reactive oxygen species in the inotropic action of ouabain on cardiac myocytes. A potential role for mitochondrial KATP channels , 2004, Molecular and Cellular Biochemistry.

[34]  Jiang Tian,et al.  Involvement of mitogen-activated protein kinases and reactive oxygen species in the inotropic action of ouabain on cardiac myocytes. A potential role for mitochondrial K ATP channels , 2003 .

[35]  H. Scher,et al.  The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  James R. Anderson,et al.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  James R. Anderson,et al.  Rhabdomyosarcoma and Undifferentiated Sarcoma in the First Two Decades of Life: A Selective Review of Intergroup Rhabdomyosarcoma Study Group Experience and Rationale for Intergroup Rhabdomyosarcoma Study V , 2001, Journal of pediatric hematology/oncology.

[38]  A. Pappo,et al.  Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  F. Barr.  Chromosomal translocations involving paired box transcription factors in human cancer. , 1997, The international journal of biochemistry & cell biology.

[40]  M. Stratton,et al.  Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. , 1989, Cancer research.

[41]  C. Sapienza,et al.  A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting , 1989 .

[42]  W. Schürch,et al.  Intermediate filament proteins and actin isoforms as markers for soft tissue tumor differentiation and origin. II. Rhabdomyosarcomas. , 1988, The American journal of pathology.

[43]  H. Shimada,et al.  Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.